Publication of Annual Report 2014 and invitation to the Annual Shareholders' Meeting to be held on 28 April 2015
March 27 2015 - 1:29PM
Mechelen,
Belgium; 27 March 2015 - Galapagos NV (Euronext: GLPG)
has the honor to invite the Shareholders, Warrant
Holders, Directors and Statutory Auditor of the Company to the
Annual Shareholders' Meeting that will be held on Tuesday 28 April
2015 at 2:00 p.m. (CET) at the registered office of the
Company.
In order to be admitted to the
Shareholders' Meeting, the holders of securities issued by the
Company must comply with article 536 of the Belgian Companies
Code and article 29 of the articles of association of the
Company, and fulfill the formalities and make the notifications
described in the convening notice.
The Annual Report 2014, convening notice, and
other relevant documents can be found at
http://www.glpg.com/index.php/companyoverview/shareholder-information/shareholder-meetings/
About
Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage
biotechnology company specialized in the discovery and development
of small molecule medicines with novel modes of action, with a
pipeline comprising three Phase 2 programs, two Phase 1 trials,
five pre-clinical studies, and 25 discovery small-molecule and
antibody programs in cystic fibrosis, inflammation, and other
indications. In the field of inflammation, AbbVie and
Galapagos signed a collaboration agreement for the development and
commercialization of filgotinib. Filgotinib is an
orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases,
currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. GLPG1205, a first-in-class inhibitor of GPR84, is
currently being tested in a Phase 2 proof-of-concept trial in
ulcerative colitis patients. GLPG1690, a first-in-class
inhibitor of autotaxin, has shown favorable safety in a Phase 1
trial and is expected to enter Phase 2 in idiopathic pulmonary
fibrosis. AbbVie and Galapagos also signed a collaboration
agreement in cystic fibrosis to develop and commercialize molecules
that address mutations in the CFTR gene. Potentiator GLPG1837
is currently in a Phase 1 trial, and corrector GLPG2222 is at the
pre-clinical candidate stage. The Galapagos Group, including
fee-for-service subsidiary Fidelta, has approximately 400
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. Further
information at: www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications &
IR
Tel: +31 6 2291 6240
ir@glpg.com
Galapagos forward-looking
statements
This release may contain forward-looking
statements, including, without limitation, expectations regarding
the commercial potential of our product candidates generally, all
of which involve certain risks and uncertainties. These
statements are often, but are not always, made through the use of
words or phrases such as "believes," "anticipates," "expects,"
"intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," "continues," "we believe," "we intend," as well as
similar expressions. Such forward-looking statements may
involve known and unknown risks, uncertainties and other factors
which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to
be materially different from any historic or future results,
financial conditions, performance or achievements expressed or
implied by such forward-looking statements. Among the factors
that may result in differences are the inherent uncertainties
associated with competitive developments, clinical trial and
product development activities, regulatory approval requirements
and estimating the commercial potential of our product
candidates. Given these uncertainties, the reader is advised
not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any such forward-looking
statements in this document to reflect any change in its
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based,
unless required by law or regulation.
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Galapagos NV via Globenewswire
HUG#1906958
Galapagos (LSE:GLPG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galapagos (LSE:GLPG)
Historical Stock Chart
From Sep 2023 to Sep 2024